Yazılar

OpenAI to Start Offering Chatbot Ads to Advertisers, Report Says

/in /tarafından

OpenAI has begun offering advertising placements within its chatbot to a select group of marketers, marking a significant shift in its business model, according to a report by The Information.

The report said OpenAI is inviting dozens of advertisers to participate in a trial period lasting several weeks, with individual spending commitments below $1 million. Ads are expected to begin appearing in early February and will be priced based on the number of views rather than clicks. Reuters could not independently verify the report, and OpenAI did not immediately comment.

OpenAI is reportedly still developing tools that would allow advertisers to buy ads directly through a self-service system. For now, the process is being handled more manually as the company tests demand and format. The move follows OpenAI’s recent decision to begin showing ads to some U.S. users, as it looks to diversify revenue beyond subscriptions.

The push into advertising underscores growing pressure on OpenAI to fund the rising costs of AI development and data center infrastructure. Backed by Microsoft, the company is widely expected to pursue a public listing in the future, increasing the need for scalable and predictable revenue streams.

New Year 2026 Personalized Wishes: Top 5 AI Prompts to Create Custom Greetings

/in /tarafından

These AI-powered prompts make it easy to craft original and personalized New Year 2026 messages using ChatGPT, Gemini, and similar tools. Devamını Oku

FDA to Review AI-Powered Mental Health Devices in November Advisory Panel

/in /tarafından

The U.S. Food and Drug Administration (FDA) announced it will convene its Digital Health Advisory Committee (DHAC) on November 6 to evaluate the growing category of AI-enabled digital mental health tools.

The meeting will explore how technologies such as chatbots, virtual therapists, and digital therapeutics could help bridge the nation’s mental health care gap, while also assessing the risks of safety, efficacy, and oversight.

Why It Matters

The U.S. faces a shortage of mental health professionals, and AI-driven platforms promise scalability, accessibility, and rapid intervention. But the speed of innovation has left regulators searching for frameworks to ensure these devices are trustworthy and clinically sound.

FDA’s Approach

  • The DHAC will advise the agency on regulatory pathways for AI/ML tools, remote monitoring, digital therapeutics, and medical device software.

  • The panel discussion is expected to help the FDA identify key areas of concern such as data privacy, bias in algorithms, and standards for clinical validation.

  • The FDA has already begun experimenting with AI in its review processes, reflecting its broader shift toward digital oversight.

Next Steps

  • The FDA has opened a public docket for comments ahead of the session.

  • Supporting materials will be made available at least two business days before the meeting.

The November discussion could shape how future AI mental health devices are classified, monitored, and approved in the U.S., setting an early precedent for regulation in this rapidly expanding sector.